高危局部晚期(pT3c)肾肿瘤的手术治疗:肿瘤学结局及改良国际转移性肾细胞癌数据库联盟(IMDC)评分的预后意义
回顾性队列研究纳入54例2007年12月至2018年4月期间转诊至单一外科与肿瘤团队的肾肿瘤累及膈周下腔静脉至右心房水平的患者,评估肿瘤学结局与长期生存;在32例接受治愈性手术的子组中评估Guy's肾癌评分(基于IMDC六项标准中的五项)的预后价值,结果显示全队列中位OS为29个月,评分分组间OS差异有统计学意义(P=0.005)。
要点
- 全队列中位OS为29个月,治愈性手术子组中位OS为32个月,减瘤子组为11个月(P=0.14)。
- 治愈性手术子组按Guy's肾癌评分分组,有利风险组(0分)未达中位OS,中危组(1分)为43个月,高危组(≥2分)为18个月(P=0.005)。
- 作者认为29个月的中位生存似可支持此类手术,Guy's肾癌评分在极高危局部晚期肿瘤患者中似有前景。
核心结论
- 中位生存29个月似乎可支持此类手术。
- 使用五项 readily available 临床指标的Guy's肾癌评分在极高危局部晚期肿瘤患者中似乎有前景。
研究设计与样本
- 回顾性队列研究,纳入2007年12月至2018年4月期间转诊至单一外科与肿瘤团队的54例患者。
- 通过电子病历获取围手术期数据与肿瘤学随访,对失访的手术患者从初级保健医生处获取生存数据。
- 采用Kaplan-Meier曲线估计总生存(OS)与无病生存。
- 在接受治愈性手术的子组(n=32)中,采用log-rank检验评估Guy's医院肾癌评分的预后价值,该评分使用IMDC预后模型六项标准中的五项(贫血、中性粒细胞增多、血小板增多、高钙血症、Karnofsky体能状态<80各计1分),以适用于M0疾病。
主要发现
- 全队列中位(IQR)OS为29(11-57)个月。
- 治愈性子组(n=32)中位(IQR)生存为32(16-57)个月,减瘤子组(n=13)为11(4-未达上限)个月(P=0.14)。
- 分析时存活患者的中位(IQR)随访时间为14(1-65)个月。
- 治愈性子组无病生存为10(6-30)个月。
- 治愈性病例按Guy's肾癌评分分组的中位(IQR)OS:有利风险组(评分=0分)未达到(无患者死亡),中危组(评分=1分)为43(30-61)个月,高危组(评分≥2分)为18(11-32)个月(P=0.005)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate contemporary oncological outcomes and long-term survival in patients undergoing surgery for urological tumours involving the peridiaphragmatic inferior vena cava up to the level of the right atrium. To apply prognostic factors developed for metastatic renal cancer to patients with very-high-risk but apparently localized tumours, and develop a scoring system. PATIENTS AND METHODS: A retrospective cohort study of 54 patients referred between December 2007 and April 2018 to a single surgical and oncological team was conducted. Electronic patient records were used to obtain peri-operative data and oncological follow-up. For operated patients lost to follow-up, survival data were obtained from primary care physicians. We used Kaplan-Meier curves to estimate overall survival (OS) and disease-free survival. For the subgroup undergoing curative surgery (n = 32) the prognostic value of a renal cancer score developed at Guy's Hospital using five of the six criteria in the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model (one point for each of anaemia, neutrophilia, thrombophilia, hypercalcaemia and Karnofsky performance status <80), in order to be relevant for M0 disease, was assessed using the log-rank test. RESULTS: The median (interquartile range [IQR]) OS of the whole cohort was 29 (11-57) months. The median (IQR) survival of the curative subgroup (n = 32) was 32 (16-57) months, vs 11 (4-upper limit not reached) months for the cytoreductive subgroup (n = 13; P = 0.14). The median (IQR) follow-up time was 14 (1-65) months for patients alive at analysis. Disease-free survival in the curative subgroup was 10 (6-30) months. The median (IQR) OS by risk category for curative cases, as defined by the Guy's renal cancer score, was not reached in the favourable risk group (score = 0 points) because there were no patient deaths, 43 (30-61) months in the intermediate-risk group (score = 1 point), and 18 months (11-32) months in the poor-risk group (score ≥ 2 points; P = 0.005). CONCLUSION: A median survival of 29 months appears to justify this type of surgery. A prognostic model, the Guy's renal cancer score, using five readily available clinical measures, appears promising in patients with very-high-risk locally advanced tumours.
引用
- Warren H, Fernando A, Thomas K, et al. Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International Metastatic Renal Cell Cancer Database Consortium (IMDC) score. BJU Int. 2019. PMID: 30908845. doi:10.1111/bju.14755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。